Review



cb receptor agonist anandamide  (Tocris)


Bioz Verified Symbol Tocris is a verified supplier
Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Tocris cb receptor agonist anandamide
    Cb Receptor Agonist Anandamide, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 197 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cb receptor agonist anandamide/product/Tocris
    Average 95 stars, based on 197 article reviews
    cb receptor agonist anandamide - by Bioz Stars, 2026-06
    95/100 stars

    Images



    Similar Products

    cb receptor agonist anandamide  (Tocris)
    95
    Tocris cb receptor agonist anandamide
    Cb Receptor Agonist Anandamide, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cb receptor agonist anandamide/product/Tocris
    Average 95 stars, based on 1 article reviews
    cb receptor agonist anandamide - by Bioz Stars, 2026-06
    95/100 stars
    		  Buy from Supplier
    cb 1 receptor agonist anandamide  (Tocris)
    95
    Tocris cb 1 receptor agonist anandamide
    Cb 1 Receptor Agonist Anandamide, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cb 1 receptor agonist anandamide/product/Tocris
    Average 95 stars, based on 1 article reviews
    cb 1 receptor agonist anandamide - by Bioz Stars, 2026-06
    95/100 stars
    		  Buy from Supplier
    endogenous cb receptor agonist anandamide  (Tocris)
    93
    Tocris endogenous cb receptor agonist anandamide
    Temporary release-independence via CB1 receptors at synapses displaying DORF. A: reconstruction of a LM-SCA and a basket cell (black soma, green axon). B: bath application of 14 μM <t>anandamide</t> (CB receptor agonist) enhanced the facilitation. C: the change in the onset of release of GABA in control and in AM-251; data for individual pairs are shown (n = 5). D: the delayed release and suppression of inhibition was blocked by 10 μM CB1 receptor antagonist, AM-251, changing the synaptic efficacy and the onset of the IPSPs, which appeared earlier during the train of action potentials elicited. E and F: bar graphs comparing the onset of first IPSPs during a train of presynaptic action potentials and IPSP latency at DORF, FDF, and depressing synapse in control and after bath application of AM-251. Onset of the first IPSP seem to be delayed at connections between LM-SCA and SCA interneurons. G: comparison of change in paired-pulse ratios (PPRs) in control and AM-251. *Significantly different than control first IPSPs.
    Endogenous Cb Receptor Agonist Anandamide, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/endogenous cb receptor agonist anandamide/product/Tocris
    Average 93 stars, based on 1 article reviews
    endogenous cb receptor agonist anandamide - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Temporary release-independence via CB1 receptors at synapses displaying DORF. A: reconstruction of a LM-SCA and a basket cell (black soma, green axon). B: bath application of 14 μM anandamide (CB receptor agonist) enhanced the facilitation. C: the change in the onset of release of GABA in control and in AM-251; data for individual pairs are shown (n = 5). D: the delayed release and suppression of inhibition was blocked by 10 μM CB1 receptor antagonist, AM-251, changing the synaptic efficacy and the onset of the IPSPs, which appeared earlier during the train of action potentials elicited. E and F: bar graphs comparing the onset of first IPSPs during a train of presynaptic action potentials and IPSP latency at DORF, FDF, and depressing synapse in control and after bath application of AM-251. Onset of the first IPSP seem to be delayed at connections between LM-SCA and SCA interneurons. G: comparison of change in paired-pulse ratios (PPRs) in control and AM-251. *Significantly different than control first IPSPs.

    Journal: Journal of Neurophysiology

    Article Title: CB1 modulation of temporally distinct synaptic facilitation among local circuit interneurons mediated by N-type calcium channels in CA1

    doi: 10.1152/jn.00831.2010

    Figure Lengend Snippet: Temporary release-independence via CB1 receptors at synapses displaying DORF. A: reconstruction of a LM-SCA and a basket cell (black soma, green axon). B: bath application of 14 μM anandamide (CB receptor agonist) enhanced the facilitation. C: the change in the onset of release of GABA in control and in AM-251; data for individual pairs are shown (n = 5). D: the delayed release and suppression of inhibition was blocked by 10 μM CB1 receptor antagonist, AM-251, changing the synaptic efficacy and the onset of the IPSPs, which appeared earlier during the train of action potentials elicited. E and F: bar graphs comparing the onset of first IPSPs during a train of presynaptic action potentials and IPSP latency at DORF, FDF, and depressing synapse in control and after bath application of AM-251. Onset of the first IPSP seem to be delayed at connections between LM-SCA and SCA interneurons. G: comparison of change in paired-pulse ratios (PPRs) in control and AM-251. *Significantly different than control first IPSPs.

    Article Snippet: The endogenous CB receptor agonist anandamide (in water soluble emulsion) (14 μM) and CB1 receptor inverse agonist/antagonists AM-251 (5 μM) (Tocris) were used to study the CB1 receptor pharmacology of IPSPs.

    Techniques: Control, Inhibition, Comparison